

CCR Second Annual Fellows and Young Investigators Retreat

February 25 ~ 27, 2002, Marriott Inner Harbor in Baltimore, MD

PROGRAM

Monday, February 25, 2002

9:00 a.m. – 9:15 a.m.

Opening Remarks

Catherine Neary, Ph.D., Chair, CCR FYI

9:15 a.m. – 10:30 a.m.

Keynote Address – p53: At the Crossroads of Molecular Carcinogenesis and the Molecular Epidemiology of Human Cancer

Curtis C. Harris, M.D., Chief, Laboratory of Human Carcinogenesis, NCI, NIH

10:30 a.m. – 11:00 a.m.

Break

11:00 a.m. – 12:30 p.m.

Oral Presentations by Attendees – Session I

Clinical/Translational Research – *Claudina Aleman, Ph.D., Moderator*

Ginger J. Gardner, M.D., Cell and Cancer Biology Branch, CCR, NCI

Peroxisome Proliferator Activated Receptor Gamma (PPAR γ) Ligands Inhibit Ovarian Cancer Cell Growth

Jeongwu Lee, Ph.D., Neuro-Oncology Branch, CCR, NCI

In vitro Expansion, Gene Expression Profiling, and Therapeutic Applications of Human Adult Bone-Marrow-Derived Neural Stem-Like Cells

Melinda S. Merchant, M.D., Ph.D., Pediatric Oncology Branch, CCR, NCI

Induction of Apoptosis in Ewings Sarcoma Cell Lines Following Treatment with Selective Tyrosine Kinase Antagonist STI571 (Imatinib Mesylate)

Sattva S. Neelapu, M.D., Experimental and Transplantation Immunology Branch, CCR, NCI

Clinical Trial of a Second Generation Lymphoma Vaccine

Hasan Zeytin, M.D., Ph.D., Laboratory of Tumor Immunology and Biology, CCR, NCI

Use of Recombinant Poxvirus Vaccines Expressing Human Carcinoembryonic Antigen (CEA) Combined with GM-CSF to Treat Mice Which Spontaneously Develop CEA-Expressing Colonic Adenomas

Signal Transduction – *Kathleen Dohoney, Ph.D., Moderator*

Bo Chen, Ph.D., Basic Research Laboratory, CCR, NCI

Drm, a BMP Antagonist, Transcriptionally Activates p21^{Cip1} and p27^{Kip1} Expression and Can Inhibit the Tumorigenic Phenotype via a Novel Mechanism

Lindsay Edwards, B.S., Laboratory of Cellular Carcinogenesis and Tumor Promotion, CCR, NCI

mtCLIC, a p53 Regulated Chloride Channel, Translocates to the Nucleus during Apoptosis

Chad Ellis, Ph.D., Cell and Cancer Biology Branch, CCR, NCI

Identification and Characterization of Rig, a Novel Farnesylated Ras-Like GTPase Exhibiting Tumor Suppressor Properties

Shiva Krupa, Ph.D., Basic Research Laboratory, CCR, NCI-Frederick

An Oncogenic c-Kit Mutant Induces Factor-Independent Growth via PI3 Kinase and Jnk-Dependent Pathways

Fang Tian, Ph.D., Laboratory of Cell Regulation and Carcinogenesis, CCR, NCI

Xenograft Models To Address the Roles of Smad2 and Smad3 in Tumorigenesis

Cancer Models and Cancer Prevention – *Jackie Lavigne, Ph.D., M.P.H., Moderator*

Klaus Felix, Ph.D., Laboratory of Genetics, CCR, NCI

Mutant Frequency in the Transgenic Target/Reporter Gene *lacZ* During Plasmacytomagenesis

Pentao Liu, Ph.D., Mouse Cancer Genetics Program, CCR, NCI-Frederick

Evi9 Can Function as a T-Cell Tumor Suppressor Gene, or a B- or Myeloid-Cell Proto-Oncogene, and Is Required for Normal B- and T-Cell Development
Binwu Tang, Ph.D., Laboratory of Cell Regulation and Carcinogenesis, CCR, NCI
 The Role of TGF- β s in Tumorigenesis from Xenografts of Human Mammary Gland Epithelia Cell Lines
Anna Maciag, Ph.D., Laboratory of Comparative Carcinogenesis, CCR, NCI-Frederick
 Expression of Mutant K-ras in Lung Epithelial Cells Increases Generation of Reactive Oxygen Species and Oxidative DNA Damage
Wafa Kammouni, Ph.D., Laboratory of Comparative Carcinogenesis, CCR, NCI-Frederick
 A Proteomic Approach in Study of Growth Arrested Epithelial-Lung Type II Cells

- 12:30 p.m. – 1:30 p.m. **Lunch**
- 1:30 p.m. – 2:00 pm **Fellows and Young Investigators Association Overview**
Catherine Neary, Ph.D., Chair, CCR FYI
Donna L. Vogel, M.D., Ph.D., Director, NCI Fellowship Office
Jonathan Wiest, Ph.D., CCR Office of the Director, NCI, NIH
- 2:00 p.m. – 3:00 p.m. **Current Experience with Clinical Translation of Antiangiogenic Therapy**
Judah Folkman, M.D., Andrus Professor of Pediatric Surgery and Director of the Surgical Research Laboratory, Children's Hospital, Boston, Massachusetts
- 3:00 p.m. – 3:30 p.m. **Break**
- 3:30 p.m. – 5:00 p.m. **Career Panel**
Christine A. Hrycyna, Ph.D., Walther Assistant Professor of Chemistry, Purdue University
Holly Symonds-Clark, Ph.D., Technology Transfer Specialist, Technology Transfer Branch, NCI, NIH
Jeffrey Silverman, Ph.D., Director, Molecular and Cellular Biology, Av Max, Inc.
Maria Sgambati, M.D., Scientific Writer, Special Communications Expert, NCI, NIH
Diana Linnekin, Ph.D., Investigator, Basic Research Laboratory, NCI, NIH
Donna L. Vogel, M.D., Ph.D., Director, NCI Fellowship Office
- 5:00 p.m. – 6:30 p.m. **Poster Session I (with Refreshments)**
Clinical/Translational Research (Westminster and Patapsco/Severn Rooms)
Signal Transduction (Westminster and Patapsco/Severn Rooms)
- 6:30 p.m. – 8:00 p.m. **Dinner**
- 7:30 p.m. – 8:30 p.m. **The Biologic Paradigm in Oncology**
Speaker: Andrew C. von Eschenbach, M.D., Director, NCI, NIH
- 8:30 p.m. – 10:00 p.m. **Social Gathering**

Tuesday, February 26, 2002

- 8:30 a.m. – 9:30 a.m. **Clinical Research and Cancer Medicine**
Speaker: Gregory A. Curt, M.D., Clinical Director, CCR, NCI, NIH
- 9:30 a.m. – 9:45 a.m. **Break**

- 9:45 a.m. – 10:45 a.m. **Career Development Workshop I – Parallel Sessions**
Sorting Out Visas at the NIH: Information for Foreign Participants at the NCI
Deborah S. Fountain, B.S., Human Resource Consultant, NCI, NIH
Interviewing Skills
Alysia Decker, M.Ed., Career Consultant, Johns Hopkins University
- 10:45 a.m. – 11:00 a.m. **Break**
- 11:00 a.m. – 12:30 p.m. **Oral Presentations by Attendees – Session II**
Pharmacology and Chemistry – Catherine Neary, Ph.D., Moderator
Ayelet Samuni, D.M.D., Ph.D., Radiation Oncology Branch, CCR, NCI
 Catecholic Estrogen Mediated Mutagenesis and Carcinogenesis: Chemoprevention Strategies with Antioxidants
Douglas D. Thomas, Ph.D., Radiation Oncology Branch, CCR, NCI
 Tyrosine Nitration from the Simultaneous Generation of Nitric Oxide and Superoxide Does Not Require Formation of Peroxynitrite: The Role of Heme
Zuben Sauna, Ph.D., Laboratory of Cell Biology, CCR, NCI
 The Role of Conserved Residues E556 and E1201 in the Walker B Domain in the Catalytic Cycle of P-glycoprotein
Takahisa Furuta, M.D., Ph.D., Laboratory of Molecular Pharmacology, CCR, NCI
 Transcription Coupled-Nucleotide Excision Repair as a Determinant of Cisplatin Activity
Lloyd Lam, Ph.D., Metabolism Branch, CCR, NCI
 Gene Expression Profiling of Chemotherapeutic Response in Lymphoma
Molecular Biology and Gene Regulation – Amit Kumar, Ph.D., Moderator
Giovanni Tonon, M.D., Genetics Branch, CCR, NCI
 Spectral Karyotyping (SKY) of the Panel of Human Cancer Cell Lines Used in a Drug-Discovery Screen by the National Cancer Institute
Shengyun Fang, M.D., Ph.D., Regulation of Protein Function Laboratory, CCR, NCI
 Implication of RING Finger Ubiquitin Ligases in Tumorigenesis and Metastasis
Kevin L. Lorick, Ph.D., Regulation of Protein Function Laboratory, CCR, NCI
 BRCA1 Is an Ubiquitin Protein Ligase Whose Activity Is Enhanced by the Non-E3 RING Protein BARD1
Frédéric Catez, Ph.D., Laboratory of Metabolism, CCR, NCI
 HMGN Chromosomal Proteins Modulate the Binding of Histone H1 to Chromatin
Xianghong H. Peng, M.D., Laboratory of Cell Biology, CCR, NCI
 Role of Conserved Tyrosine401 and Tyrosine1044 in the Nucleotide-Binding Domains of Human P-glycoprotein in Mgatp Binding and Catalytic Activity
Immunology and Infectious Diseases – Elizabeth Read-Connole, Ph.D., Moderator
Jennifer L. Troyer, Ph.D., Laboratory of Genomic Diversity, CCR, NCI
 FIV-Screening and Sequence Analysis in Wild Feline Species
Yuuei Shu, Ph.D., Laboratory of Experimental and Computational Biology, CCR, NCI-Frederick
 Novel Broadly Cross-Reactive HIV-1 Neutralizing Human Monoclonal Antibody Selected for Binding to gp120-CD4-CCR5 Complexes
Terry J. Fry, M.D., Pediatric Oncology Branch, CCR, NCI
 Progressive Tumor Growth Does Not Induce Tolerance but Instead Induces Weak Immunity
Stephen C. Bunnell, Ph.D., Laboratory of Cellular and Molecular Biology, CCR, NCI
 Visualizing Signaling Assemblies: Dynamic Complex Formation During T Cell Activation
Y. Jeffrey Chiang, Ph.D., Experimental Immunology Branch, CCR, NCI
 Cbl-b Deficiency Reveals a CD28 Independent Role for B7 Costimulation
- 12:30 p.m. – 2:00 p.m. **Poster Session II (with Lunch)**
Molecular Biology and Gene Regulation (Stadium Ballroom)

2:00 p.m. – 3:30 p.m.	Poster Session III Pharmacology and Chemistry (<i>Westminster Room</i>) Cancer Models and Cancer Prevention (<i>Patapsco/Severn Rooms</i>) Immunology and Infectious Diseases (<i>Patapsco/Severn Rooms</i>)
3:30 p.m. – 4:00 p.m.	Break
4:00 p.m. – 5:00 p.m.	Career Development Workshop II – Parallel Sessions Jobs in Industry <i>William T. Schrader, Ph.D., Vice President for Research and Development and Chief Scientific Officer, XenoPharm, Inc.</i> Setting Up a Lab <i>Russell Hovey, Ph.D., Assistant Professor, Department of Animal Science, University of Vermont</i> <i>Matthew F. Mackey, Ph.D., Molecular Immunologist, Aventis Pharmaceuticals</i> Effective Presentation Skills and Use of Visual Aids <i>Richard A. Sloane, M.S., Resource Recovery Specialist and Educator, NIEHS, NIH</i>
5:00 p.m. – 5:30 p.m.	Closing Remarks <i>Lee Helmam, M.D., Chief, Pediatric Oncology Branch, CCR, NCI, NIH</i>
5:30 p.m.	Adjourn